X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (715) 715
Patent (83) 83
Publication (55) 55
Book Chapter (6) 6
Reference (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (298) 298
hematology (175) 175
middle aged (173) 173
female (172) 172
male (171) 171
index medicus (166) 166
adult (162) 162
aged (159) 159
prognosis (111) 111
aged, 80 and over (108) 108
oncology (102) 102
leukemia, myeloid, acute - genetics (90) 90
chemistry (85) 85
acute myeloid-leukemia (84) 84
microbiology (84) 84
beer (83) 83
biochemistry (83) 83
compositions or test papers therefor (83) 83
condition-responsive control in microbiological orenzymological processes (83) 83
enzymology (83) 83
measuring or testing processes involving enzymes, nucleicacids or microorganisms (83) 83
metallurgy (83) 83
mutation or genetic engineering (83) 83
processes of preparing such compositions (83) 83
spirits (83) 83
vinegar (83) 83
wine (83) 83
mutation (77) 77
physics (71) 71
adolescent (69) 69
acute myelogenous leukemia (64) 64
minimal residual disease (62) 62
investigating or analysing materials by determining theirchemical or physical properties (61) 61
measuring (61) 61
testing (61) 61
genetics & heredity (59) 59
cytogenetics (54) 54
karyotyping (53) 53
leukemia (53) 53
young adult (50) 50
chromosome aberrations (47) 47
acute myeloid leukemia (42) 42
in situ hybridization, fluorescence (42) 42
acute disease (41) 41
aml (41) 41
cancer (36) 36
hemic and lymphatic diseases (35) 35
leukemia, myeloid - genetics (35) 35
analysis (34) 34
translocation, genetic (34) 34
acute lymphoblastic-leukemia (33) 33
polymerase chain reaction (33) 33
mutations (32) 32
abridged index medicus (31) 31
cohort studies (31) 31
genetic aspects (31) 31
nuclear proteins - genetics (31) 31
immunophenotyping (30) 30
internal tandem duplication (30) 30
leukemia, myeloid, acute - diagnosis (30) 30
diagnosis (28) 28
fms-like tyrosine kinase 3 - genetics (28) 28
leukemia, myeloid, acute - pathology (28) 28
myelodysplastic syndromes - genetics (28) 28
survival analysis (28) 28
acute promyelocytic leukemia (27) 27
classification (27) 27
myelodysplastic syndrome (27) 27
gene (26) 26
gene expression (25) 25
leukemia, myeloid, acute - mortality (25) 25
oncogene proteins, fusion - genetics (25) 25
recurrence (25) 25
dna-binding proteins - genetics (24) 24
gene expression profiling (24) 24
myeloproliferative disorders - genetics (24) 24
biomarkers, tumor - genetics (23) 23
hematology, oncology and palliative medicine (23) 23
expression (22) 22
mutation - genetics (22) 22
reverse transcriptase polymerase chain reaction (22) 22
risk factors (22) 22
animals (21) 21
disease-free survival (21) 21
follow-up studies (21) 21
myelodysplastic syndromes (21) 21
research (21) 21
normal karyotype (20) 20
survival rate (20) 20
child (19) 19
chromosome banding (19) 19
dna mutational analysis (19) 19
genetic research (19) 19
prognostic-significance (19) 19
core binding factor alpha 2 subunit - genetics (18) 18
flow cytometry (18) 18
janus kinase 2 - genetics (18) 18
neoplasm proteins - genetics (18) 18
abnormalities (17) 17
genes (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 24, pp. 2305 - 2315
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2428 - 2436
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Nature Genetics, ISSN 1061-4036, 01/2013, Volume 45, Issue 1, pp. 18 - 24
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2008, Volume 105, Issue 10, pp. 3945 - 3950
Journal Article
Genes, Chromosomes and Cancer, ISSN 1045-2257, 04/2013, Volume 52, Issue 4, pp. 410 - 422
Journal Article
Journal Article
Journal Article